Skip to content

D&A at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$67.15M-44.2%
Elanco Animal Health Inc. logo
Elanco Animal Health Inc.ELAN
$138M+7.8%
Opko Health logo
Opko HealthOPK
$18.97M-4.5%
HWK
HawkinsHWKN
$13.58M+28.3%
Zoetis logo
ZoetisZTS
Revvity logo
RevvityRVTY

Segments

By segment

See full
Food Safety$26.5M+3.1%
Animal Safety$2.4M-35.1%

Other financials

Income statement

See full
Revenue$211.2M-4.4%
Gross profit$99.0M-10.2%
Operating income-$3.3M-161%
Net income-$17.0M-56.0%
EPS (diluted)-$0.08-60.0%

Balance sheet

See full
Cash & equivalents$159.9M+25.2%
Total debt$793.3M-11.2%
Total equity$2.1B-21.0%
Total assets$3.4B-16.8%

Cash flow

See full
Operating cash flow$22.7M+16.7%
CapEx$11.6M-64.7%
Free cash flow$11.1M+182%

Valuation

See full
Market cap$2B+12.0%
Enterprise value$2.63B+4.4%
P/S2.3×+0.3×

Profitability

See full
Gross margin45.2%-3.6pp
Operating margin-73.1%+77.7pp
Net margin-69.9%+30.8pp
FCF margin-14%

Returns & leverage

See full
Return on equity-25.6%+28.8pp
Debt / equity0.4×0.0×
Current ratio3.9×0.0×

Where this comes from

Reported directly by Neogen in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Neogen’s 10-Q, filed April 9, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neogen's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neogen's D&A?
Neogen (NEOG) reported D&A of $28.92M in Q4 2025.
How has Neogen's D&A changed year-over-year?
Neogen's D&A decreased by 1.5% year-over-year, from $29.35M to $28.92M.
What is the long-term trend for Neogen's D&A?
Over 4 years (2021 to 2025), Neogen's D&A has grown at a 54.4% compound annual growth rate (CAGR), from $21.04M to $119.48M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.